NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Imcyse

Imcyse

Private
LiègeHealthcare & Life Scienceshttps://imcyse.com/

Last Round

Series B

Extension

Feb 17, 2021

Total Funding Raised

$66.18M

Company Overview

Imcyse is a biotechnology company that develops active specific immunotherapies for the treatment and prevention of severe chronic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticalautoimmune diseaseantigen-specific immunotherapyimmune tolerancepeptide therapyclinical-stage biotechdrug developmenttype 1 diabetesrheumatoid arthritisdrug licensingprecision medicineimmunomodulationbiotech partneringtherapeutic platform

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Imcyse Comparables

Compare Imcyse with similar companies based on industry and business-model similarity.

Imcyse comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Anokion
88%
COUR Pharmaceuticals
86%
Worg Pharmaceuticals
82%

Imcyse Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionFeb 17, 2021
GrantJul 28, 2020
DebtJun 18, 2019
GrantJun 18, 2019
Series BJun 18, 2019
Grant
Jun 6, 2017

Imcyse Investors

Notable investors and investment history

Imcyse investors
InvestorRounds
Federal Holding and Investment CompanySeries B Extension, Series B
EQT Life SciencesSeries B Extension, Series B
NoshaqSeries B Extension, Series B
EpimedeSeries B Extension, Series B
Société Régionale d'Investissement de WallonieSeries B Extension, Series B
KU LeuvenSeries B Extension, Series B
PfizerSeries B Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 17, 2021

    $26M round led by Pfizer

  • Jun 18, 2019

    $32M round led by EQT Life Sciences.

Imcyse Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Imcyse Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Imcyse's valuation, stock price, and market status.

Firmographic Details

HeadquartersLiège
Employee Range5
Year Founded2010
Last FundingFeb 17, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.